These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 29906709)

  • 1. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials.
    Zheng W; Cai DB; Yang XH; Li L; Zhang QE; Ng CH; Ungvari GS; Li XB; Ning YP; Xiang YT
    J Psychiatr Res; 2018 Aug; 103():244-251. PubMed ID: 29906709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials.
    Zheng W; Xiang YT; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Correll CU
    Acta Psychiatr Scand; 2016 Nov; 134(5):385-398. PubMed ID: 27585549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.
    Kishi T; Nosaka T; Sakuma K; Okuya M; Iwata N
    Neuropsychopharmacol Rep; 2020 Sep; 40(3):314-322. PubMed ID: 32767739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
    Goldman R; Loebel A; Cucchiaro J; Deng L; Findling RL
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):516-525. PubMed ID: 28475373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
    Samalin L; Ben Gharbia M; Garnier M; Llorca PM
    Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.
    Correll CU; Maayan L; Kane J; Hert MD; Cohen D
    J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
    Loebel A; Cucchiaro J; Silva R; Mao Y; Xu J; Pikalov A; Marder SR
    Eur Psychiatry; 2015 Jan; 30(1):26-31. PubMed ID: 25280429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients.
    Higuchi T; Ishigooka J; Iyo M; Yeh CB; Ebenezer EG; Liang KY; Lee JS; Lee SY; Lin SK; Yoon BH; Nakamura M; Hagi K; Sato T
    Asia Pac Psychiatry; 2019 Jun; 11(2):e12352. PubMed ID: 30950208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
    Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
    Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
    Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
    Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.
    Pompili M; Verzura C; Trovini G; Buscajoni A; Falcone G; Naim S; Nardella A; Sorice S; Baldessarini RJ; Girardi P
    Expert Opin Drug Saf; 2018 Feb; 17(2):197-205. PubMed ID: 28902525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.
    Miura I; Horikoshi S; Ichinose M; Suzuki Y; Watanabe K
    Drug Des Devel Ther; 2023; 17():3023-3031. PubMed ID: 37789971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
    Tandon R; Cucchiaro J; Phillips D; Hernandez D; Mao Y; Pikalov A; Loebel A
    J Psychopharmacol; 2016 Jan; 30(1):69-77. PubMed ID: 26645209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.